{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:08Z","timestamp":1794009068099,"version":"4.8.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"DOI":"10.1038\/s41574-026-01277-2","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:02:28Z","timestamp":1785398548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-9451","authenticated-orcid":false,"given":"Birgitte R.","family":"Kornum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8399-4308","authenticated-orcid":false,"given":"Alberte Wollesen","family":"Breum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Mincikiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1946-1125","authenticated-orcid":false,"given":"Stine","family":"Knudsen-Heier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"1277_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1055\/s-0029-1237117","volume":"29","author":"N Goel","year":"2009","unstructured":"Goel, N., Rao, H., Durmer, J. S. & Dinges, D. F. Neurocognitive consequences of sleep deprivation. Semin. Neurol. 29, 320\u2013339 (2009).","journal-title":"Semin. Neurol."},{"key":"1277_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/15500594221090067","volume":"54","author":"RR Gilley","year":"2023","unstructured":"Gilley, R. R. The role of sleep in cognitive function: the value of a good night\u2019s rest. Clin. EEG Neurosci. 54, 12\u201320 (2023).","journal-title":"Clin. EEG Neurosci."},{"key":"1277_CR3","doi-asserted-by":"publisher","first-page":"109269","DOI":"10.1016\/j.neuropsychologia.2025.109269","volume":"219","author":"EC Sullivan","year":"2025","unstructured":"Sullivan, E. C., McCall, C., Henderson, L.-M. & Cairney, S. A. Disentangling sleep\u2019s role in emotion processing. Neuropsychologia 219, 109269 (2025).","journal-title":"Neuropsychologia"},{"key":"1277_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrn2762","volume":"11","author":"S Diekelmann","year":"2010","unstructured":"Diekelmann, S. & Born, J. The memory function of sleep. Nat. Rev. Neurosci. 11, 114\u2013126 (2010).","journal-title":"Nat. Rev. Neurosci."},{"key":"1277_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10198-013-0491-2","volume":"15","author":"P Jennum","year":"2014","unstructured":"Jennum, P., Ibsen, R., Avlund, K. & Kjellberg, J. Health, social and economic consequences of hypersomnia: a controlled national study from a national registry evaluating the societal effect on patients and their partners. Eur. J. Health Econ. 15, 303\u2013311 (2014).","journal-title":"Eur. J. Health Econ."},{"key":"1277_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/thx.2010.143958","volume":"66","author":"P Jennum","year":"2011","unstructured":"Jennum, P. & Kjellberg, J. Health, social and economical consequences of sleep-disordered breathing: a controlled national study. Thorax 66, 560\u2013566 (2011).","journal-title":"Thorax"},{"key":"1277_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.sleh.2022.09.010","volume":"9","author":"J-P Chaput","year":"2023","unstructured":"Chaput, J.-P. et al. Economic burden of insomnia symptoms in Canada. Sleep Health 9, 185\u2013189 (2023).","journal-title":"Sleep Health"},{"key":"1277_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41386-019-0444-2","volume":"45","author":"BE Jones","year":"2020","unstructured":"Jones, B. E. Arousal and sleep circuits. Neuropsychopharmacology 45, 6\u201320 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"1277_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/JHD-230564","volume":"12","author":"M Nollet","year":"2023","unstructured":"Nollet, M., Franks, N. P. & Wisden, W. Understanding sleep regulation in normal and pathological conditions, and why it matters. J. Huntingt. Dis. 12, 105\u2013119 (2023).","journal-title":"J. Huntingt. Dis."},{"key":"1277_CR10","first-page":"195","volume":"1","author":"AA Borb\u00e9ly","year":"1982","unstructured":"Borb\u00e9ly, A. A. A two process model of sleep regulation. Hum. Neurobiol. 1, 195\u2013204 (1982).","journal-title":"Hum. Neurobiol."},{"key":"1277_CR11","unstructured":"Berry, R. et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications (American Academy of Sleep Medicine, 2017)."},{"key":"1277_CR12","doi-asserted-by":"publisher","first-page":"8733","DOI":"10.1073\/pnas.93.16.8733","volume":"93","author":"KM Gautvik","year":"1996","unstructured":"Gautvik, K. M. et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proc. Natl Acad. Sci. USA 93, 8733\u20138738 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea, L. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA 95, 322\u2013327 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573\u2013585 (1998).","journal-title":"Cell"},{"key":"1277_CR15","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996\u201310015 (1998).","journal-title":"J. Neurosci."},{"key":"1277_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0702780","volume":"128","author":"D Smart","year":"1999","unstructured":"Smart, D. et al. Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br. J. Pharmacol. 128, 1\u20133 (1999).","journal-title":"Br. J. Pharmacol."},{"key":"1277_CR17","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1523\/JNEUROSCI.18-19-07962.1998","volume":"18","author":"AN van den Pol","year":"1998","unstructured":"van den Pol, A. N., Gao, X. B., Obrietan, K., Kilduff, T. S. & Belousov, A. B. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin\/orexin. J. Neurosci. 18, 7962\u20137971 (1998).","journal-title":"J. Neurosci."},{"key":"1277_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fnins.2020.00691","volume":"14","author":"S Soya","year":"2020","unstructured":"Soya, S. & Sakurai, T. Evolution of orexin neuropeptide system: structure and function. Front. Neurosci. 14, 691 (2020).","journal-title":"Front. Neurosci."},{"key":"1277_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","volume":"98","author":"L Lin","year":"1999","unstructured":"Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365\u2013376 (1999).","journal-title":"Cell"},{"key":"1277_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437\u2013451 (1999).","journal-title":"Cell"},{"key":"1277_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991\u2013997 (2000).","journal-title":"Nat. Med."},{"key":"1277_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","volume":"27","author":"TC Thannickal","year":"2000","unstructured":"Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469\u2013474 (2000).","journal-title":"Neuron"},{"key":"1277_CR23","first-page":"1","volume":"45","author":"L de Lecea","year":"2021","unstructured":"de Lecea, L. Twenty-three years of hypocretins: the \u2018Rosetta Stone\u2019 of sleep\/arousal circuits. Front. Neurol. Neurosci. 45, 1\u201310 (2021).","journal-title":"Front. Neurol. Neurosci."},{"key":"1277_CR24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0306-4522(01)00319-0","volume":"106","author":"RA Espa\u00f1a","year":"2001","unstructured":"Espa\u00f1a, R. A., Baldo, B. A., Kelley, A. E. & Berridge, C. W. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience 106, 699\u2013715 (2001).","journal-title":"Neuroscience"},{"key":"1277_CR25","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1523\/JNEUROSCI.23-08-03555.2003","volume":"23","author":"JM Zeitzer","year":"2003","unstructured":"Zeitzer, J. M. et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J. Neurosci. 23, 3555\u20133560 (2003).","journal-title":"J. Neurosci."},{"key":"1277_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0006-3223(02)01740-7","volume":"54","author":"RM Salomon","year":"2003","unstructured":"Salomon, R. M. et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96\u2013104 (2003).","journal-title":"Biol. Psychiatry"},{"key":"1277_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2461","volume":"4","author":"AM Blouin","year":"2013","unstructured":"Blouin, A. M. et al. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat. Commun. 4, 1547 (2013).","journal-title":"Nat. Commun."},{"key":"1277_CR28","doi-asserted-by":"publisher","first-page":"E2635","DOI":"10.1073\/pnas.1202526109","volume":"109","author":"ME Carter","year":"2012","unstructured":"Carter, M. E. et al. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc. Natl Acad. Sci. USA 109, E2635\u2013E2644 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0028-3908(00)00178-7","volume":"40","author":"RE Brown","year":"2001","unstructured":"Brown, R. E., Sergeeva, O., Eriksson, K. S. & Haas, H. L. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 40, 457\u2013459 (2001).","journal-title":"Neuropharmacology"},{"key":"1277_CR30","doi-asserted-by":"publisher","first-page":"9965","DOI":"10.1073\/pnas.181330998","volume":"98","author":"ZL Huang","year":"2001","unstructured":"Huang, Z. L. et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl Acad. Sci. USA 98, 9965\u20139970 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/sj.npp.1300807","volume":"31","author":"NM Vittoz","year":"2006","unstructured":"Vittoz, N. M. & Berridge, C. W. Hypocretin\/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area. Neuropsychopharmacology 31, 384\u2013395 (2006).","journal-title":"Neuropsychopharmacology"},{"key":"1277_CR32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2301951120","volume":"120","author":"H Ito","year":"2023","unstructured":"Ito, H. et al. Deficiency of orexin signaling during sleep is involved in abnormal REM sleep architecture in narcolepsy. Proc. Natl Acad. Sci. USA 120, e2301951120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17401-3","volume":"11","author":"H Feng","year":"2020","unstructured":"Feng, H. et al. Orexin signaling modulates synchronized excitation in the sublaterodorsal tegmental nucleus to stabilize REM sleep. Nat. Commun. 11, 3661 (2020).","journal-title":"Nat. Commun."},{"key":"1277_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-193413010-00001","volume":"13","author":"LE Daniels","year":"1934","unstructured":"Daniels, L. E. Narcolepsy. Medicine 13, 1 (1934).","journal-title":"Medicine"},{"key":"1277_CR35","doi-asserted-by":"publisher","first-page":"106496","DOI":"10.1016\/j.sleep.2025.106496","volume":"131","author":"Y Inoue","year":"2025","unstructured":"Inoue, Y., Kumagai, T., Shoji, A., Kokubo, K. & Honda, M. Clinical challenges in narcolepsy: from delayed diagnosis to daytime function impairments during treatment. Sleep Med. 131, 106496 (2025).","journal-title":"Sleep Med."},{"key":"1277_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40263-024-01142-8","volume":"39","author":"LE Ortiz","year":"2025","unstructured":"Ortiz, L. E. et al. A survey of people living with narcolepsy in the USA: path to diagnosis, quality of life, and treatment landscape from the patient\u2019s perspective. CNS Drugs 39, 23\u201336 (2025).","journal-title":"CNS Drugs"},{"key":"1277_CR37","unstructured":"American Academy of Sleep Medicine. International Classification of Sleep Disorders 3rd ed. (American Academy of Sleep Medicine, 2023)."},{"key":"1277_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/00005053-193003000-00001","volume":"71","author":"C Von Economo","year":"1930","unstructured":"Von Economo, C. Sleep as a problem of localization. J. Nerv. Ment. Dis. 71, 249\u2013259 (1930).","journal-title":"J. Nerv. Ment. Dis."},{"key":"1277_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.100","volume":"3","author":"BR Kornum","year":"2017","unstructured":"Kornum, B. R. et al. Narcolepsy. Nat. Rev. Dis. Primers 3, 16100 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1277_CR40","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1212\/WNL.57.11.2029","volume":"57","author":"Y Dauvilliers","year":"2001","unstructured":"Dauvilliers, Y. et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 57, 2029\u20132033 (2001).","journal-title":"Neurology"},{"key":"1277_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5664\/jcsm.3370","volume":"10","author":"C Won","year":"2014","unstructured":"Won, C. et al. The impact of gender on timeliness of narcolepsy diagnosis. J. Clin. Sleep Med. 10, 89\u201395 (2014).","journal-title":"J. Clin. Sleep Med."},{"key":"1277_CR42","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/sleep\/32.8.979","volume":"32","author":"A Aran","year":"2009","unstructured":"Aran, A. et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32, 979\u2013983 (2009).","journal-title":"Sleep"},{"key":"1277_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.sleep.2024.02.033","volume":"116","author":"JK Gool","year":"2024","unstructured":"Gool, J. K. et al. Potential immunological triggers for narcolepsy and idiopathic hypersomnia: real-world insights on infections and influenza vaccinations. Sleep Med. 116, 105\u2013114 (2024).","journal-title":"Sleep Med."},{"key":"1277_CR44","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.sleep.2013.03.020","volume":"14","author":"MS Heier","year":"2013","unstructured":"Heier, M. S. et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med. 14, 867\u2013871 (2013).","journal-title":"Sleep Med."},{"key":"1277_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.smrv.2017.06.006","volume":"38","author":"TO Sarkanen","year":"2018","unstructured":"Sarkanen, T. O., Alakuijala, A. P. E., Dauvilliers, Y. A. & Partinen, M. M. Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med. Rev. 38, 177\u2013186 (2018).","journal-title":"Sleep Med. Rev."},{"key":"1277_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1399-0039.1984.tb02144.x","volume":"24","author":"T Juji","year":"1984","unstructured":"Juji, T., Satake, M., Honda, Y. & Doi, Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24, 316\u2013319 (1984).","journal-title":"Tissue Antigens"},{"key":"1277_CR47","first-page":"1012","volume":"20","author":"E Mignot","year":"1997","unstructured":"Mignot, E., Hayduk, R., Black, J., Grumet, F. C. & Guilleminault, C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20, 1012\u20131020 (1997).","journal-title":"Sleep"},{"key":"1277_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa055","volume":"43","author":"BR Kornum","year":"2020","unstructured":"Kornum, B. R. Narcolepsy type 1: what have we learned from immunology? Sleep 43, zsaa055 (2020).","journal-title":"Sleep"},{"key":"1277_CR49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220911120","volume":"120","author":"A Seifinejad","year":"2023","unstructured":"Seifinejad, A. et al. Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy. Proc. Natl Acad. Sci. USA 120, e2220911120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08774-1","volume":"10","author":"NW Pedersen","year":"2019","unstructured":"Pedersen, N. W. et al. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat. Commun. 10, 837 (2019).","journal-title":"Nat. Commun."},{"key":"1277_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41586-018-0540-1","volume":"562","author":"D Latorre","year":"2018","unstructured":"Latorre, D. et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature 562, 63\u201368 (2018).","journal-title":"Nature"},{"key":"1277_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5665\/sleep.2320","volume":"36","author":"A Savvidou","year":"2013","unstructured":"Savvidou, A. et al. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy. Sleep 36, 147\u2013148 (2013).","journal-title":"Sleep"},{"key":"1277_CR53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/sleep\/33.2.169","volume":"33","author":"S Knudsen","year":"2010","unstructured":"Knudsen, S., Jennum, P. J., Alving, J., Sheikh, S. P. & Gammeltoft, S. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Sleep 33, 169\u2013176 (2010).","journal-title":"Sleep"},{"key":"1277_CR54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/sleep\/30.8.969","volume":"30","author":"MS Heier","year":"2007","unstructured":"Heier, M. S. et al. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 30, 969\u2013973 (2007).","journal-title":"Sleep"},{"key":"1277_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2024.08.003","volume":"53","author":"M Josler","year":"2024","unstructured":"Josler, M. et al. CSF-profile and hypocretin levels in children with narcolepsy type 1 and 2. Eur. J. Paediatr. Neurol. 53, 1\u20137 (2024).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1277_CR56","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","volume":"57","author":"B Ripley","year":"2001","unstructured":"Ripley, B. et al. CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions. Neurology 57, 2253\u20132258 (2001).","journal-title":"Neurology"},{"key":"1277_CR57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1474-4422(08)70140-6","volume":"7","author":"P Bourgin","year":"2008","unstructured":"Bourgin, P., Zeitzer, J. M. & Mignot, E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol. 7, 649\u2013662 (2008).","journal-title":"Lancet Neurol."},{"key":"1277_CR58","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/jnnp.74.12.1667","volume":"74","author":"Y Dauvilliers","year":"2003","unstructured":"Dauvilliers, Y. et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J. Neurol. Neurosurg. Psychiatry 74, 1667\u20131673 (2003).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1277_CR59","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0014-4886(03)00388-1","volume":"184","author":"D Gerashchenko","year":"2003","unstructured":"Gerashchenko, D. et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp. Neurol. 184, 1010\u20131016 (2003).","journal-title":"Exp. Neurol."},{"key":"1277_CR60","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.5665\/sleep.2080","volume":"35","author":"O Andlauer","year":"2012","unstructured":"Andlauer, O. et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 35, 1247\u20131255 (2012).","journal-title":"Sleep"},{"key":"1277_CR61","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","volume":"38","author":"JT Willie","year":"2003","unstructured":"Willie, J. T. et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38, 715\u2013730 (2003).","journal-title":"Neuron"},{"key":"1277_CR62","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1172\/JCI71017","volume":"124","author":"E Hasegawa","year":"2014","unstructured":"Hasegawa, E., Yanagisawa, M., Sakurai, T. & Mieda, M. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J. Clin. Invest. 124, 604\u2013616 (2014).","journal-title":"J. Clin. Invest."},{"key":"1277_CR63","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.cub.2025.03.040","volume":"35","author":"T Ishikawa","year":"2025","unstructured":"Ishikawa, T. et al. An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions. Curr. Biol. 35, 2088\u20132099.e4 (2025).","journal-title":"Curr. Biol."},{"key":"1277_CR64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207531119","volume":"119","author":"R Evans","year":"2022","unstructured":"Evans, R. et al. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proc. Natl Acad. Sci. USA 119, e2207531119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR65","first-page":"1119","volume":"31","author":"K Mishima","year":"2008","unstructured":"Mishima, K. et al. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep 31, 1119\u20131126 (2008).","journal-title":"Sleep"},{"key":"1277_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac103","volume":"45","author":"AE van der Hoeven","year":"2022","unstructured":"van der Hoeven, A. E. et al. Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification. Sleep 45, zsac103 (2022).","journal-title":"Sleep"},{"key":"1277_CR67","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","volume":"59","author":"E Mignot","year":"2002","unstructured":"Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553\u20131562 (2002).","journal-title":"Arch. Neurol."},{"key":"1277_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2021.100101","volume":"11","author":"JP Kukkonen","year":"2021","unstructured":"Kukkonen, J. P. What do I talk about when I talk about measuring CNS orexin-A? Considerations of orexin-a measurements in clinical and preclinical setting. Med. Drug Discov. 11, 100101 (2021).","journal-title":"Med. Drug Discov."},{"key":"1277_CR69","doi-asserted-by":"publisher","first-page":"106505","DOI":"10.1016\/j.sleep.2025.106505","volume":"131","author":"JP Kukkonen","year":"2025","unstructured":"Kukkonen, J. P., Turunen, P. M. & Rinne, M. K. Detection of reduced orexin-A\/hypocretin-1 and its fragments by orexin-A \u2018gold-standard\u2019 radioimmunoassay. Sleep Med. 131, 106505 (2025).","journal-title":"Sleep Med."},{"key":"1277_CR70","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.5664\/jcsm.10014","volume":"18","author":"T Sarkanen","year":"2022","unstructured":"Sarkanen, T., Sved, G., Juuj\u00e4rvi, M., Alakuijala, A. & Partinen, M. Misdiagnosis of narcolepsy caused by a false-positive orexin-A\/hypocretin-1 enzyme immune assay. J. Clin. Sleep Med. 18, 2075\u20132078 (2022).","journal-title":"J. Clin. Sleep Med."},{"key":"1277_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaf237","volume":"48","author":"J Vialaret","year":"2025","unstructured":"Vialaret, J. et al. 16-mer hypocretin-1\/orexin-A in cerebrospinal fluid to diagnose narcolepsy. Sleep 48, zsaf237 (2025).","journal-title":"Sleep"},{"key":"1277_CR72","doi-asserted-by":"publisher","first-page":"14958","DOI":"10.1021\/acs.analchem.6c00454","volume":"98","author":"Y Cao","year":"2026","unstructured":"Cao, Y. et al. Tackling the orexin conundrum: an optimized LC-MS\/MS method demonstrates accurate CSF quantification and absence in peripheral blood. Anal. Chem. 98, 14958\u201314966 (2026).","journal-title":"Anal. Chem."},{"key":"1277_CR73","doi-asserted-by":"publisher","unstructured":"Wenz, E. S. et al. Hypocretin-1\/orexin-A fragment1-16 as a potential surrogate marker for diagnosing narcolepsy type 1. Sleep https:\/\/doi.org\/10.1093\/sleep\/zsag115 (2026).","DOI":"10.1093\/sleep\/zsag115"},{"key":"1277_CR74","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1021\/acs.analchem.9b02710","volume":"91","author":"K B\u00e5rdsen","year":"2019","unstructured":"B\u00e5rdsen, K. et al. Considerably lower levels of hypocretin-1 in cerebrospinal fluid is revealed by a novel mass spectrometry method compared with standard radioimmunoassay. Anal. Chem. 91, 9323\u20139329 (2019).","journal-title":"Anal. Chem."},{"key":"1277_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab050","volume":"3","author":"HM \u00c6gidius","year":"2021","unstructured":"\u00c6gidius, H. M. et al. Pre-treatment of blood samples reveal normal blood hypocretin\/orexin signal in narcolepsy type 1. Brain Commun. 3, fcab050 (2021).","journal-title":"Brain Commun."},{"key":"1277_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.sleep.2020.12.037","volume":"79","author":"A Dietmann","year":"2021","unstructured":"Dietmann, A., Gallino, C., Wenz, E., Mathis, J. & Bassetti, C. L. A. Multiple sleep latency test and polysomnography in patients with central disorders of hypersomnolence. Sleep Med. 79, 6\u201310 (2021).","journal-title":"Sleep Med."},{"key":"1277_CR77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neurol.2016.09.016","volume":"173","author":"C Monaca","year":"2017","unstructured":"Monaca, C., Franco, P., Philip, P. & Dauvilliers, Y. French consensus. Type 1 and type 2 narcolepsy: investigations and follow-up. Rev. Neurol. 173, 25\u201331 (2017).","journal-title":"Rev. Neurol."},{"key":"1277_CR78","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1093\/brain\/awt277","volume":"136","author":"F Pizza","year":"2013","unstructured":"Pizza, F. et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 136, 3787\u20133795 (2013).","journal-title":"Brain"},{"key":"1277_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36942-8","volume":"9","author":"N Sakai","year":"2019","unstructured":"Sakai, N., Matsumura, M., Lin, L., Mignot, E. & Nishino, S. HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. Sci. Rep. 9, 477 (2019).","journal-title":"Sci. Rep."},{"key":"1277_CR80","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.5665\/sleep.5140","volume":"38","author":"M Kawai","year":"2015","unstructured":"Kawai, M., O\u2019Hara, R., Einen, M., Lin, L. & Mignot, E. Narcolepsy in African Americans. Sleep 38, 1673\u20131681 (2015).","journal-title":"Sleep"},{"key":"1277_CR81","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.5665\/sleep.3758","volume":"37","author":"A Goldbart","year":"2014","unstructured":"Goldbart, A. et al. Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort. Sleep 37, 1043\u20131051 (2014).","journal-title":"Sleep"},{"key":"1277_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13203","volume":"30","author":"H Baumann-Vogel","year":"2021","unstructured":"Baumann-Vogel, H., Schreckenbauer, L., Valko, P. O., Werth, E. & Baumann, C. R. Narcolepsy type 2: a rare, yet existing entity. J. Sleep Res. 30, e13203 (2021).","journal-title":"J. Sleep Res."},{"key":"1277_CR83","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jsmc.2023.01.003","volume":"18","author":"M Blattner","year":"2023","unstructured":"Blattner, M. & Maski, K. Narcolepsy and idiopathic hypersomnia. Sleep Med. Clin. 18, 183\u2013199 (2023).","journal-title":"Sleep Med. Clin."},{"key":"1277_CR84","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CLA Bassetti","year":"2019","unstructured":"Bassetti, C. L. A. et al. Narcolepsy\u00a0\u2014 clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat. Rev. Neurol. 15, 519\u2013539 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1277_CR85","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/sleep\/32.8.993","volume":"32","author":"TC Thannickal","year":"2009","unstructured":"Thannickal, T. C., Nienhuis, R. & Siegel, J. M. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 32, 993\u2013998 (2009).","journal-title":"Sleep"},{"key":"1277_CR86","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1212\/WNL.0000000000001051","volume":"83","author":"F Pizza","year":"2014","unstructured":"Pizza, F. et al. Primary progressive narcolepsy type 1: the other side of the coin. Neurology 83, 2189\u20132190 (2014).","journal-title":"Neurology"},{"key":"1277_CR87","doi-asserted-by":"publisher","first-page":"zsw010","DOI":"10.1093\/sleep\/zsw010","volume":"40","author":"R Lopez","year":"2017","unstructured":"Lopez, R. et al. Temporal changes in the cerebrospinal fluid level of hypocretin-1 and histamine in narcolepsy. Sleep 40, zsw010 (2017).","journal-title":"Sleep"},{"key":"1277_CR88","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuroscience.2007.05.029","volume":"148","author":"S Zhang","year":"2007","unstructured":"Zhang, S. et al. The development of hypocretin (orexin) deficiency in hypocretin\/ataxin-3 transgenic rats. Neuroscience 148, 34\u201343 (2007).","journal-title":"Neuroscience"},{"key":"1277_CR89","doi-asserted-by":"publisher","first-page":"10956","DOI":"10.1073\/pnas.1603325113","volume":"113","author":"R Bernard-Valnet","year":"2016","unstructured":"Bernard-Valnet, R. et al. CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc. Natl Acad. Sci. USA 113, 10956\u201310961 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR90","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","volume":"34","author":"S Tabuchi","year":"2014","unstructured":"Tabuchi, S. et al. Conditional ablation of orexin\/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J. Neurosci. 34, 6495\u20136509 (2014).","journal-title":"J. Neurosci."},{"key":"1277_CR91","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40675-020-00195-7","volume":"6","author":"K Spruyt","year":"2020","unstructured":"Spruyt, K. Narcolepsy presentation in diverse populations: an update. Curr. Sleep Med. Rep. 6, 239\u2013250 (2020).","journal-title":"Curr. Sleep Med. Rep."},{"key":"1277_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123512","volume":"473","author":"S-G Berntsson","year":"2025","unstructured":"Berntsson, S.-G. et al. Post-vaccination hypersomnia - occurrence of idiopathic hypersomnia and narcolepsy type 2 after Pandemrix vaccination in a case- series from Sweden and Finland. J. Neurol. Sci. 473, 123512 (2025).","journal-title":"J. Neurol. Sci."},{"key":"1277_CR93","doi-asserted-by":"publisher","first-page":"zsag025","DOI":"10.1093\/sleep\/zsag025","volume":"49","author":"Y Dauvilliers","year":"2026","unstructured":"Dauvilliers, Y. Perspectives on idiopathic hypersomnia: diagnostic challenges, unknown pathophysiological, and emerging therapeutic strategies. Sleep 49,\u00a0zsag025\u00a0(2026).","journal-title":"Sleep"},{"key":"1277_CR94","first-page":"31","volume":"119","author":"B Roth","year":"1976","unstructured":"Roth, B. Narcolepsy and hypersomnia: review and classification of 642 personally observed cases. Schweiz. Arch. Neurol. Neurochir. Psychiatr. 119, 31\u201341 (1976).","journal-title":"Schweiz. Arch. Neurol. Neurochir. Psychiatr."},{"key":"1277_CR95","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/NSS.S266090","volume":"14","author":"M Billiard","year":"2022","unstructured":"Billiard, M. & Sonka, K. Idiopathic hypersomnia: historical account, critical review of current tests and criteria, diagnostic evaluation in the absence of biological markers and robust electrophysiological diagnostic criteria. Nat. Sci. Sleep 14, 311\u2013322 (2022).","journal-title":"Nat. Sci. Sleep"},{"key":"1277_CR96","doi-asserted-by":"publisher","first-page":"e2387","DOI":"10.1212\/WNL.0000000000200519","volume":"98","author":"JK Gool","year":"2022","unstructured":"Gool, J. K. et al. Data-driven phenotyping of central disorders of hypersomnolence with unsupervised clustering. Neurology 98, e2387\u2013e2400 (2022).","journal-title":"Neurology"},{"key":"1277_CR97","doi-asserted-by":"publisher","first-page":"789","DOI":"10.5664\/jcsm.2922","volume":"9","author":"LM Trotti","year":"2013","unstructured":"Trotti, L. M., Staab, B. A. & Rye, D. B. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J. Clin. Sleep Med. 9, 789\u2013795 (2013).","journal-title":"J. Clin. Sleep Med."},{"key":"1277_CR98","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5664\/jcsm.6882","volume":"14","author":"C Ruoff","year":"2018","unstructured":"Ruoff, C. et al. The MSLT is repeatable in narcolepsy type 1 but not narcolepsy type 2: a retrospective patient study. J. Clin. Sleep Med. 14, 65\u201374 (2018).","journal-title":"J. Clin. Sleep Med."},{"key":"1277_CR99","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa044","volume":"43","author":"R Fronczek","year":"2020","unstructured":"Fronczek, R. et al. To split or to lump? Classifying the central disorders of hypersomnolence. Sleep 43, zsaa044 (2020).","journal-title":"Sleep"},{"key":"1277_CR100","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-0404.1991.tb03969.x","volume":"83","author":"C Hublin","year":"1991","unstructured":"Hublin, C., Partinen, M. & Koskimies, S. Familial narcolepsy in Finland. Acta Neurol. Scand. 83, 388\u2013393 (1991).","journal-title":"Acta Neurol. Scand."},{"key":"1277_CR101","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/sleep\/30.7.851","volume":"30","author":"L Chen","year":"2007","unstructured":"Chen, L. et al. The familial risk and HLA susceptibility among narcolepsy patients in Hong Kong Chinese. Sleep 30, 851\u2013858 (2007).","journal-title":"Sleep"},{"key":"1277_CR102","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41525-022-00298-w","volume":"7","author":"T Miyagawa","year":"2022","unstructured":"Miyagawa, T. et al. A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia. NPJ Genom. Med. 7, 29 (2022).","journal-title":"NPJ Genom. Med."},{"key":"1277_CR103","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1183\/09031936.00016808","volume":"33","author":"J-L P\u00e9pin","year":"2009","unstructured":"P\u00e9pin, J.-L. et al. Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur. Respir. J. 33, 1062\u20131067 (2009).","journal-title":"Eur. Respir. J."},{"key":"1277_CR104","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/sleep\/30.6.711","volume":"30","author":"TE Weaver","year":"2007","unstructured":"Weaver, T. E. et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 30, 711\u2013719 (2007).","journal-title":"Sleep"},{"key":"1277_CR105","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.sleepx.2024.100126","volume":"8","author":"S Miano","year":"2024","unstructured":"Miano, S., Kheirandish-Gozal, L. & De Pieri, M. Comorbidity of obstructive sleep apnea and narcolepsy: a challenging diagnosis and complex management. Sleep Med. X 8, 100126 (2024).","journal-title":"Sleep Med. X"},{"key":"1277_CR106","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1046\/j.0962-1105.2003.00373.x","volume":"12","author":"T Kanbayashi","year":"2003","unstructured":"Kanbayashi, T. et al. CSF hypocretin measures in patients with obstructive sleep apnea. J. Sleep Res. 12, 339\u2013341 (2003).","journal-title":"J. Sleep Res."},{"key":"1277_CR107","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.sleep.2023.05.001","volume":"107","author":"RK Bogan","year":"2023","unstructured":"Bogan, R. K. et al. Safety and pharmacodynamics of a single infusion of danavorexton in adults with obstructive sleep apnea experiencing excessive daytime sleepiness despite adequate use of CPAP. Sleep Med. 107, 229\u2013235 (2023).","journal-title":"Sleep Med."},{"key":"1277_CR108","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.sleep.2022.10.016","volume":"101","author":"S Sithirungson","year":"2023","unstructured":"Sithirungson, S., Sonsuwan, N., Chattipakorn, S. C., Chattipakorn, N. & Shinlapawittayatorn, K. Functional roles of orexin in obstructive sleep apnea: from clinical observation to mechanistic insights. Sleep Med. 101, 40\u201349 (2023).","journal-title":"Sleep Med."},{"key":"1277_CR109","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.1073\/pnas.0702676104","volume":"104","author":"RH Williams","year":"2007","unstructured":"Williams, R. H., Jensen, L. T., Verkhratsky, A., Fugger, L. & Burdakov, D. Control of hypothalamic orexin neurons by acid and CO2. Proc. Natl Acad. Sci. USA 104, 10685\u201310690 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1277_CR110","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fneur.2015.00109","volume":"6","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y., Fenik, P., Zhan, G., Xin, R. & Veasey, S. C. Degeneration in arousal neurons in chronic sleep disruption modeling sleep apnea. Front. Neurol. 6, 109 (2015).","journal-title":"Front. Neurol."},{"key":"1277_CR111","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/sleep\/27.2.194","volume":"27","author":"SC Veasey","year":"2004","unstructured":"Veasey, S. C. et al. Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep-wake brain regions. Sleep 27, 194\u2013201 (2004).","journal-title":"Sleep"},{"key":"1277_CR112","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13628","volume":"31","author":"L Palagini","year":"2022","unstructured":"Palagini, L., Hertenstein, E., Riemann, D. & Nissen, C. Sleep, insomnia and mental health. J. Sleep Res. 31, e13628 (2022).","journal-title":"J. Sleep Res."},{"key":"1277_CR113","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/smrv.2002.0186","volume":"6","author":"MM Ohayon","year":"2002","unstructured":"Ohayon, M. M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med. Rev. 6, 97\u2013111 (2002).","journal-title":"Sleep Med. Rev."},{"key":"1277_CR114","first-page":"129","volume":"8","author":"DJ Buysse","year":"2011","unstructured":"Buysse, D. J., Germain, A., Hall, M., Monk, T. H. & Nofzinger, E. A. A neurobiological model of insomnia. Drug Discov. Today 8, 129\u2013137 (2011).","journal-title":"Drug Discov. Today"},{"key":"1277_CR115","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc2590","volume":"6","author":"S-B Li","year":"2020","unstructured":"Li, S.-B. et al. Hypothalamic circuitry underlying stress-induced insomnia and peripheral immunosuppression. Sci. Adv. 6, eabc2590 (2020).","journal-title":"Sci. Adv."},{"key":"1277_CR116","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh3021","volume":"375","author":"S-B Li","year":"2022","unstructured":"Li, S.-B. et al. Hyperexcitable arousal circuits drive sleep instability during aging. Science 375, eabh3021 (2022).","journal-title":"Science"},{"key":"1277_CR117","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.psyneuen.2015.12.011","volume":"65","author":"LM Federici","year":"2016","unstructured":"Federici, L. M. et al. Hypothalamic orexin\u2019s role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model. Psychoneuroendocrinology 65, 127\u2013137 (2016).","journal-title":"Psychoneuroendocrinology"},{"key":"1277_CR118","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1212\/WNL.59.4.639","volume":"59","author":"RP Allen","year":"2002","unstructured":"Allen, R. P., Mignot, E., Ripley, B., Nishino, S. & Earley, C. J. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 59, 639\u2013641 (2002).","journal-title":"Neurology"},{"key":"1277_CR119","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213466","volume":"104","author":"S Chenini","year":"2025","unstructured":"Chenini, S. et al. Association of sleep disruption with daytime sleepiness in patients with restless legs syndrome. Neurology 104, e213466 (2025).","journal-title":"Neurology"},{"key":"1277_CR120","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1212\/01.WNL.0000094196.50155.38","volume":"61","author":"K Stiasny-Kolster","year":"2003","unstructured":"Stiasny-Kolster, K. et al. CSF hypocretin-1 levels in restless legs syndrome. Neurology 61, 1426\u20131429 (2003).","journal-title":"Neurology"},{"key":"1277_CR121","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1124\/pharmrev.123.000953","volume":"76","author":"JP Kukkonen","year":"2024","unstructured":"Kukkonen, J. P., Jacobson, L. H., Hoyer, D., Rinne, M. K. & Borgland, S. L. International union of basic and clinical pharmacology CXIV: orexin receptor function, nomenclature and pharmacology. Pharmacol. Rev. 76, 625\u2013688 (2024).","journal-title":"Pharmacol. Rev."},{"key":"1277_CR122","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000514963","volume":"45","author":"Y Sun","year":"2021","unstructured":"Sun, Y., Tisdale, R. K. & Kilduff, T. S. Hypocretin\/orexin receptor pharmacology and sleep phases. Front. Neurol. Neurosci. 45, 22\u201337 (2021).","journal-title":"Front. Neurol. Neurosci."},{"key":"1277_CR123","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","volume":"82","author":"A Markham","year":"2022","unstructured":"Markham, A. Daridorexant: first approval. Drugs 82, 601\u2013607 (2022).","journal-title":"Drugs"},{"key":"1277_CR124","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/joim.13406","volume":"291","author":"LH Jacobson","year":"2022","unstructured":"Jacobson, L. H., Hoyer, D. & de Lecea, L. Hypocretins (orexins): the ultimate translational neuropeptides. J. Intern. Med. 291, 533\u2013556 (2022).","journal-title":"J. Intern. Med."},{"key":"1277_CR125","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg, R. et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw. Open 2, e1918254 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1277_CR126","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa080","volume":"43","author":"TC Neylan","year":"2020","unstructured":"Neylan, T. C. et al. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 43, zsaa080 (2020).","journal-title":"Sleep"},{"key":"1277_CR127","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5664\/jcsm.8294","volume":"16","author":"P Murphy","year":"2020","unstructured":"Murphy, P., Kumar, D., Zammit, G., Rosenberg, R. & Moline, M. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening. J. Clin. Sleep Med. 16, 765\u2013773 (2020).","journal-title":"J. Clin. Sleep Med."},{"key":"1277_CR128","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac068","volume":"45","author":"TA Mellman","year":"2022","unstructured":"Mellman, T. A., Birku, K., Sandhu, I., Lavela, P. & Kobayashi, I. Evaluation of suvorexant for trauma-related insomnia. Sleep 45, zsac068 (2022).","journal-title":"Sleep"},{"key":"1277_CR129","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5664\/jcsm.5382","volume":"12","author":"H Sun","year":"2016","unstructured":"Sun, H. et al. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J. Clin. Sleep Med. 12, 9\u201317 (2016).","journal-title":"J. Clin. Sleep Med."},{"key":"1277_CR130","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021043","volume":"99","author":"S Xu","year":"2020","unstructured":"Xu, S., Cui, Y., Shen, J. & Wang, P. Suvorexant for the prevention of delirium: a meta-analysis. Medicine 99, e21043 (2020).","journal-title":"Medicine"},{"key":"1277_CR131","unstructured":"GSK. GSK and Actelion Discontinue Clinical Development of Almorexant https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-and-actelion-discontinue-clinical-development-of-almorexant\/ (2011)."},{"key":"1277_CR132","doi-asserted-by":"publisher","first-page":"174117","DOI":"10.1016\/j.pbb.2025.174117","volume":"258","author":"S Chaki","year":"2026","unstructured":"Chaki, S. & Imadera, Y. Dual orexin receptor antagonists in insomnia: toward a new therapeutic paradigm. Pharmacol. Biochem. Behav. 258, 174117 (2026).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1277_CR133","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cpt.1046","volume":"104","author":"C Muehlan","year":"2018","unstructured":"Muehlan, C. et al. Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin. Pharmacol. Ther. 104, 1022\u20131029 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1277_CR134","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bcpt.13930","volume":"133","author":"D Kambe","year":"2023","unstructured":"Kambe, D. et al. Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant\/TS-142 in healthy Japanese participants following single\/multiple dosing: randomized, double-blind, placebo-controlled phase-1 studies. Basic Clin. Pharmacol. Toxicol. 133, 576\u2013591 (2023).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"1277_CR135","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/10398562221092310","volume":"30","author":"NA Keks","year":"2022","unstructured":"Keks, N. A. & Hope, J. Lemborexant, an orexin receptor antagonist sedative-hypnotic: is it useful for insomnia in psychiatric disorders? Australas. Psychiatry 30, 530\u2013532 (2022).","journal-title":"Australas. Psychiatry"},{"key":"1277_CR136","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/cpdd.817","volume":"10","author":"I Landry","year":"2021","unstructured":"Landry, I. et al. Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults. Clin. Pharmacol. Drug Dev. 10, 153\u2013165 (2021).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"1277_CR137","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.2147\/DDDT.S73224","volume":"9","author":"EL Sutton","year":"2015","unstructured":"Sutton, E. L. Profile of suvorexant in the management of insomnia. Drug Des. Dev. Ther. 9, 6035\u20136042 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"1277_CR138","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40263-023-01020-9","volume":"37","author":"T Di Marco","year":"2023","unstructured":"Di Marco, T. et al. Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem. CNS Drugs 37, 639\u2013653 (2023).","journal-title":"CNS Drugs"},{"key":"1277_CR139","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/10600280221143794","volume":"57","author":"J Park","year":"2023","unstructured":"Park, J., Render, K. P. & Cates, D. W. Daridorexant: comprehensive review of a new oral agent for the treatment of insomnia. Ann. Pharmacother. 57, 1076\u20131087 (2023).","journal-title":"Ann. Pharmacother."},{"key":"1277_CR140","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"WJ Herring","year":"2020","unstructured":"Herring, W. J. et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial. Alzheimers Dement. 16, 541\u2013551 (2020).","journal-title":"Alzheimers Dement."},{"key":"1277_CR141","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.sleep.2017.05.009","volume":"36","author":"J Black","year":"2017","unstructured":"Black, J. et al. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference. Sleep Med. 36, 86\u201394 (2017).","journal-title":"Sleep Med."},{"key":"1277_CR142","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5664\/jcsm.6800","volume":"13","author":"P Murphy","year":"2017","unstructured":"Murphy, P. et al. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study. J. Clin. Sleep Med. 13, 1289\u20131299 (2017).","journal-title":"J. Clin. Sleep Med."},{"key":"1277_CR143","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","volume":"87","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers, Y. et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann. Neurol. 87, 347\u2013356 (2020).","journal-title":"Ann. Neurol."},{"key":"1277_CR144","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","volume":"94","author":"G Zammit","year":"2020","unstructured":"Zammit, G. et al. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology 94, e2222\u2013e2232 (2020).","journal-title":"Neurology"},{"key":"1277_CR145","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae098","volume":"47","author":"T Di Marco","year":"2024","unstructured":"Di Marco, T. et al. Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies. Sleep 47, zsae098 (2024).","journal-title":"Sleep"},{"key":"1277_CR146","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","volume":"79","author":"WJ Herring","year":"2016","unstructured":"Herring, W. J. et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol. Psychiatry 79, 136\u2013148 (2016).","journal-title":"Biol. Psychiatry"},{"key":"1277_CR147","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/7854_2016_47","volume":"33","author":"LH Jacobson","year":"2017","unstructured":"Jacobson, L. H., Chen, S., Mir, S. & Hoyer, D. Orexin OX2 receptor antagonists as sleep aids. Curr. Top. Behav. Neurosci. 33, 105\u2013136 (2017).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"1277_CR148","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nm1544","volume":"13","author":"C Brisbare-Roch","year":"2007","unstructured":"Brisbare-Roch, C. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150\u2013155 (2007).","journal-title":"Nat. Med."},{"key":"1277_CR149","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.smrv.2020.101332","volume":"53","author":"JW Clark","year":"2020","unstructured":"Clark, J. W., Brian, M. L., Drummond, S. P. A., Hoyer, D. & Jacobson, L. H. Effects of orexin receptor antagonism on human sleep architecture: a systematic review. Sleep Med. Rev. 53, 101332 (2020).","journal-title":"Sleep Med. Rev."},{"key":"1277_CR150","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fnins.2014.00028","volume":"8","author":"C Dugovic","year":"2014","unstructured":"Dugovic, C. et al. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front. Neurosci. 8, 28 (2014).","journal-title":"Front. Neurosci."},{"key":"1277_CR151","doi-asserted-by":"publisher","first-page":"108743","DOI":"10.1016\/j.sleep.2025.108743","volume":"139","author":"C Unger","year":"2026","unstructured":"Unger, C. & Kohlmeier, K. A. Pharmacological management of insomnia with a focus on GABAA receptor positive allosteric modulators and orexin receptor antagonists. Sleep Med. 139, 108743 (2026).","journal-title":"Sleep Med."},{"key":"1277_CR152","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fphar.2013.00165","volume":"4","author":"MA Steiner","year":"2013","unstructured":"Steiner, M. A., Sciarretta, C., Pasquali, A. & Jenck, F. The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front. Pharmacol. 4, 165 (2013).","journal-title":"Front. Pharmacol."},{"key":"1277_CR153","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1124\/jpet.114.220392","volume":"352","author":"P Bonaventure","year":"2015","unstructured":"Bonaventure, P. et al. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J. Pharmacol. Exp. Ther. 352, 590\u2013601 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1277_CR154","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1038\/npp.2011.129","volume":"36","author":"A Gozzi","year":"2011","unstructured":"Gozzi, A. et al. Neuroimaging evidence of altered fronto-cortical and striatal function after prolonged cocaine self-administration in the rat. Neuropsychopharmacology 36, 2431\u20132440 (2011).","journal-title":"Neuropsychopharmacology"},{"key":"1277_CR155","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fphar.2017.00357","volume":"8","author":"P Bonaventure","year":"2017","unstructured":"Bonaventure, P. et al. Evaluation of JNJ-54717793 a novel brain penetrant selective orexin 1 receptor antagonist in two rat models of panic attack provocation. Front. Pharmacol. 8, 357 (2017).","journal-title":"Front. Pharmacol."},{"key":"1277_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016406","volume":"6","author":"A Gozzi","year":"2011","unstructured":"Gozzi, A. et al. Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS ONE 6, e16406 (2011).","journal-title":"PLoS ONE"},{"key":"1277_CR157","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039131","volume":"7","author":"SR Morairty","year":"2012","unstructured":"Morairty, S. R. et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE 7, e39131 (2012).","journal-title":"PLoS ONE"},{"key":"1277_CR158","doi-asserted-by":"publisher","first-page":"zsy141","DOI":"10.1093\/sleep\/zsy141","volume":"41","author":"S-B Li","year":"2018","unstructured":"Li, S.-B., Nev\u00e1rez, N., Giardino, W. J. & de Lecea, L. Optical probing of orexin\/hypocretin receptor antagonists. Sleep 41, zsy141 (2018).","journal-title":"Sleep"},{"key":"1277_CR159","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.115.225466","volume":"354","author":"P Bonaventure","year":"2015","unstructured":"Bonaventure, P. et al. Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J. Pharmacol. Exp. Ther. 354, 471\u2013482 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1277_CR160","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1177\/0269881118773745","volume":"32","author":"P De Boer","year":"2018","unstructured":"De Boer, P. et al. A randomized phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J. Psychopharmacol. 32, 668\u2013677 (2018).","journal-title":"J. Psychopharmacol."},{"key":"1277_CR161","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41386-021-01175-3","volume":"47","author":"VL Revell","year":"2022","unstructured":"Revell, V. L. et al. Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial. Neuropsychopharmacology 47, 719\u2013727 (2022).","journal-title":"Neuropsychopharmacology"},{"key":"1277_CR162","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.molmed.2022.10.008","volume":"29","author":"JL Justinussen","year":"2023","unstructured":"Justinussen, J. L., Egebjerg, C. & Kornum, B. R. How hypocretin agonists may improve the quality of wake in narcolepsy. Trends Mol. Med. 29, 61\u201369 (2023).","journal-title":"Trends Mol. Med."},{"key":"1277_CR163","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/ctn7030028","volume":"7","author":"R Fronczek","year":"2023","unstructured":"Fronczek, R. & Lammers, G. J. Narcolepsy type 1: should we only target hypocretin receptor 2? Clin. Transl. Neurosci. 7, 28 (2023).","journal-title":"Clin. Transl. Neurosci."},{"key":"1277_CR164","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/13543784.2018.1459561","volume":"27","author":"S Takenoshita","year":"2018","unstructured":"Takenoshita, S. et al. An overview of hypocretin based therapy in narcolepsy. Expert Opin. Investig. Drugs 27, 389\u2013406 (2018).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1277_CR165","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13878","volume":"32","author":"R Evans","year":"2023","unstructured":"Evans, R. et al. Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals. J. Sleep Res. 32, e13878 (2023).","journal-title":"J. Sleep Res."},{"key":"1277_CR166","doi-asserted-by":"publisher","first-page":"A56","DOI":"10.1093\/sleep\/zsaa056.140","volume":"43","author":"H Kimura","year":"2020","unstructured":"Kimura, H. & Ishikawa, T. TAK-925, an orexin 2 receptor-selective agonist, enhanced cortical arousal in a narcolepsy mouse model different from effects of modafinil. Sleep 43, A56 (2020).","journal-title":"Sleep"},{"key":"1277_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70594-1","volume":"14","author":"K Mitsukawa","year":"2024","unstructured":"Mitsukawa, K. et al. TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Sci. Rep. 14, 20838 (2024).","journal-title":"Sci. Rep."},{"key":"1277_CR168","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2301940","volume":"389","author":"Y Dauvilliers","year":"2023","unstructured":"Dauvilliers, Y. et al. Oral orexin receptor 2 agonist in narcolepsy type 1. N. Engl. J. Med. 389, 309\u2013321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1277_CR169","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa2405847","volume":"392","author":"Y Dauvilliers","year":"2025","unstructured":"Dauvilliers, Y. et al. Oveporexton, an oral orexin receptor 2\u2013selective agonist, in narcolepsy type 1. N. Engl. J. Med. 392, 1905\u20131916 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1277_CR170","unstructured":"Takeda Pharmaceuticals. U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda\u2019s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 https:\/\/www.takeda.com\/newsroom\/newsreleases\/2026\/fda-accepts-nda-priority-review-oveporexton-narcolepsy-type-1\/ (2026)."},{"key":"1277_CR171","unstructured":"NLS Pharmaceutics AG. NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=7532257755931036 (2024)."},{"key":"1277_CR172","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.117.241596","volume":"362","author":"A Treiber","year":"2017","unstructured":"Treiber, A. et al. The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468. J. Pharmacol. Exp. Ther. 362, 489\u2013503 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1277_CR173","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","volume":"29","author":"C Muehlan","year":"2019","unstructured":"Muehlan, C., Brooks, S., Zuiker, R., van Gerven, J. & Dingemanse, J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur. Neuropsychopharmacol. 29, 847\u2013857 (2019).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1277_CR174","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/cmdc.202000453","volume":"15","author":"C Boss","year":"2020","unstructured":"Boss, C. et al. The quest for the best dual orexin receptor antagonist (daridorexant) for the treatment of insomnia disorders. ChemMedChem 15, 2286\u20132305 (2020).","journal-title":"ChemMedChem"},{"key":"1277_CR175","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsy260","volume":"42","author":"A Vermeeren","year":"2019","unstructured":"Vermeeren, A. et al. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep 42, zsy260 (2019).","journal-title":"Sleep"},{"key":"1277_CR176","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/00325481.2020.1823724","volume":"133","author":"M Moline","year":"2021","unstructured":"Moline, M. et al. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. Postgrad. Med. 133, 71\u201381 (2021).","journal-title":"Postgrad. Med."},{"key":"1277_CR177","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4, M. et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 43, zsaa123 (2020).","journal-title":"Sleep"},{"key":"1277_CR178","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1021\/jm100541c","volume":"53","author":"CD Cox","year":"2010","unstructured":"Cox, C. D. et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 53, 5320\u20135332 (2010).","journal-title":"Med. Chem."},{"key":"1277_CR179","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.neuropharm.2011.10.003","volume":"62","author":"CJ Winrow","year":"2012","unstructured":"Winrow, C. J. et al. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology 62, 978\u2013987 (2012).","journal-title":"Neuropharmacology"},{"key":"1277_CR180","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","volume":"79","author":"WJ Herring","year":"2012","unstructured":"Herring, W. J. et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79, 2265\u20132274 (2012).","journal-title":"Neurology"},{"key":"1277_CR181","first-page":"259","volume":"36","author":"H Sun","year":"2013","unstructured":"Sun, H. et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 36, 259\u2013267 (2013).","journal-title":"Sleep"},{"key":"1277_CR182","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.5665\/sleep.4068","volume":"37","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 37, 1609\u20131619 (2014).","journal-title":"Sleep"},{"key":"1277_CR183","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","volume":"13","author":"D Michelson","year":"2014","unstructured":"Michelson, D. et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 13, 461\u2013471 (2014).","journal-title":"Lancet Neurol."},{"key":"1277_CR184","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sleep.2015.10.007","volume":"19","author":"E Snyder","year":"2016","unstructured":"Snyder, E. et al. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med. 19, 93\u2013100 (2016).","journal-title":"Sleep Med."},{"key":"1277_CR185","unstructured":"Pharma Japan. Japan Approves 3 New Drugs, Expands Label for Enhertu, Silgard 9 and More https:\/\/pj.jiho.jp\/article\/253641 (2025)."},{"key":"1277_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115489","volume":"28","author":"A Futamura","year":"2020","unstructured":"Futamura, A. et al. Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia. Bioorg. Med. Chem. 28, 115489 (2020).","journal-title":"Bioorg. Med. Chem."},{"key":"1277_CR187","doi-asserted-by":"publisher","first-page":"A58","DOI":"10.1093\/sleep\/zsaa056.144","volume":"43","author":"M Uchiyama","year":"2020","unstructured":"Uchiyama, M. et al. Efficacy and safety of single dose of TS-142, a novel and potent dual orexin receptor antagonist, in insomnia patients. Sleep 43, A58 (2020).","journal-title":"Sleep"},{"key":"1277_CR188","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","volume":"239","author":"M Uchiyama","year":"2022","unstructured":"Uchiyama, M. et al. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study. Psychopharmacology 239, 2143\u20132154 (2022).","journal-title":"Psychopharmacology"},{"key":"1277_CR189","doi-asserted-by":"publisher","first-page":"zsaf291","DOI":"10.1093\/sleep\/zsaf291","volume":"49","author":"M Uchiyama","year":"2026","unstructured":"Uchiyama, M. et al. Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study. Sleep 49, zsaf291 (2026).","journal-title":"Sleep"},{"key":"1277_CR190","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70217","volume":"14","author":"S Kamigaso","year":"2026","unstructured":"Kamigaso, S. et al. Estimation of the orexin receptor occupancy from human plasma pharmacokinetics of vornorexant, a novel dual orexin 1\/2 receptor antagonist for the treatment of insomnia. Pharmacol. Res. Perspect. 14, e70217 (2026).","journal-title":"Pharmacol. Res. Perspect."},{"key":"1277_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1814155","volume":"17","author":"Q Li","year":"2026","unstructured":"Li, Q. et al. Single-dose pharmacokinetics, tolerability, and physiologically based pharmacokinetic modeling of Fazamorexant in Chinese patients with hepatic impairment and in healthy controls. Front. Pharmacol. 17, 1814155 (2026).","journal-title":"Front. Pharmacol."},{"key":"1277_CR192","unstructured":"Cerevance. CVN766 Psychiatric & CNS-Controlled Metabolic Disorders https:\/\/www.cerevance.com\/studies\/cvn766 (2025)."},{"key":"1277_CR193","doi-asserted-by":"publisher","first-page":"129629","DOI":"10.1016\/j.bmcl.2024.129629","volume":"100","author":"A Glen","year":"2024","unstructured":"Glen, A. et al. Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist. Bioorg. Med. Chem. Lett. 100, 129629 (2024).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1277_CR194","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0553-z","volume":"9","author":"K Recourt","year":"2019","unstructured":"Recourt, K. et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl. Psychiatry 9, 216 (2019).","journal-title":"Transl. Psychiatry"},{"key":"1277_CR195","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0269881118822258","volume":"33","author":"S Brooks","year":"2019","unstructured":"Brooks, S. et al. The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J. Psychopharmacol. 33, 202\u2013209 (2019).","journal-title":"J. Psychopharmacol."},{"key":"1277_CR196","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/s41380-024-02846-5","volume":"30","author":"S Mesens","year":"2024","unstructured":"Mesens, S. et al. Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial. Mol. Psychiatry 30, 2427\u20132435\u00a0(2024).","journal-title":"Mol. Psychiatry"},{"key":"1277_CR197","doi-asserted-by":"publisher","first-page":"16830","DOI":"10.1007\/s10489-022-04357-8","volume":"53","author":"M Dutt","year":"2023","unstructured":"Dutt, M., Redhu, S., Goodwin, M. & Omlin, C. W. SleepXAI: an explainable deep learning approach for multi-class sleep stage identification. Appl. Intell. 53, 16830\u201316843 (2023).","journal-title":"Appl. Intell."},{"key":"1277_CR198","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.neuron.2005.03.010","volume":"46","author":"T Sakurai","year":"2005","unstructured":"Sakurai, T. et al. Input of orexin\/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron 46, 297\u2013308 (2005).","journal-title":"Neuron"},{"key":"1277_CR199","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0474-23.2024","volume":"11","author":"Y Tsuneoka","year":"2024","unstructured":"Tsuneoka, Y. & Funato, H. Whole brain mapping of orexin receptor mRNA expression visualized by branched in situ hybridization chain reaction. eNeuro 11, ENEURO.0474-23.2024 (2024).","journal-title":"eNeuro"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01277-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01277-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01277-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:14:03Z","timestamp":1785521643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01277-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":199,"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01277-2","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"22 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.R.K. is the founder and CEO of the biotech spinout company Ceremedy Aps. S.K.-H. is a member of the European Narcolepsy Advisory Board and is involved in a registry-based study sponsored by Takeda. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}